Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice
- PMID:19484222
- DOI: 10.1007/s00213-009-1568-6
Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice
Abstract
Rationale: Due to its intrinsic deficiency in prepulse inhibition (PPI), the inbred DBA/2 mouse strain has been considered as an animal model for evaluating antipsychotic drugs. However, the PPI impairment observed in DBA/2 mice relative to the common C57BL/6 strain is confounded by a concomitant reduction in baseline startle reactivity. In this study, we examined the robustness of the PPI deficit when this confound is fully taken into account.
Materials and methods: Male DBA/2 and C57BL/6 mice were compared in a PPI experiment using multiple pulse stimulus intensities, allowing the possible matching of startle reactivity prior to examination of PPI. The known PPI-enhancing effect of the antipsychotic, clozapine, was then evaluated in half of the animals, whilst the other half was subjected to two additional schizophrenia-relevant behavioural tests: latent inhibition (LI) and locomotor reaction to the psychostimulants-amphetamine and phencyclidine.
Results: PPI deficiency in DBA/2 relative to C57BL/6 mice was essentially independent of the strain difference in baseline startle reactivity. Yet, there was no evidence that DBA/2 mice were superior in detecting the PPI-facilitating effect of clozapine when startle difference was balanced. Compared with C57BL/6 mice, DBA/2 mice also showed impaired LI and a different temporal profile in their responses to amphetamine and phencyclidine.
Conclusion: Relative to the C57BL/6 strain, DBA/2 mice displayed multiple behavioural traits relevant to schizophrenia psycho- and physiopathology, indicative of both dopaminergic and glutamatergic/N-methyl-D: -aspartic acid receptor dysfunctions. Further examination of their underlying neurobiological differences is therefore warranted in order to enhance the power of this specific inter-strain comparison as a model of schizophrenia.
Similar articles
- Prepulse inhibition of the startle reflex and response to antipsychotic treatments in two outbred mouse strains in comparison to the inbred DBA/2 mouse.Flood DG, Zuvich E, Marino MJ, Gasior M.Flood DG, et al.Psychopharmacology (Berl). 2011 Jun;215(3):441-54. doi: 10.1007/s00213-011-2196-5. Epub 2011 Feb 8.Psychopharmacology (Berl). 2011.PMID:21301810
- The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics?Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z, Brunner D.Olivier B, et al.Psychopharmacology (Berl). 2001 Jul;156(2-3):284-90. doi: 10.1007/s002130100828.Psychopharmacology (Berl). 2001.PMID:11549230
- Activation of GABA(B) receptors reverses spontaneous gating deficits in juvenile DBA/2J mice.Bortolato M, Frau R, Orrù M, Piras AP, Fà M, Tuveri A, Puligheddu M, Gessa GL, Castelli MP, Mereu G, Marrosu F.Bortolato M, et al.Psychopharmacology (Berl). 2007 Oct;194(3):361-9. doi: 10.1007/s00213-007-0845-5. Epub 2007 Jun 29.Psychopharmacology (Berl). 2007.PMID:17604981
- Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR.Geyer MA, et al.Psychopharmacology (Berl). 2001 Jul;156(2-3):117-54. doi: 10.1007/s002130100811.Psychopharmacology (Berl). 2001.PMID:11549216Review.
- [Evaluation of antipsychotic and relative drugs using disruption of prepulse inhibition as an animal model for schizophrenia].Suemaru K, Kohnomi S, Umeda K, Araki H.Suemaru K, et al.Nihon Shinkei Seishin Yakurigaku Zasshi. 2008 Jun;28(3):121-6.Nihon Shinkei Seishin Yakurigaku Zasshi. 2008.PMID:18646597Review.Japanese.
Cited by
- A conceptual and practical guide to the behavioural evaluation of animal models of the symptomatology and therapy of schizophrenia.Yee BK, Singer P.Yee BK, et al.Cell Tissue Res. 2013 Oct;354(1):221-46. doi: 10.1007/s00441-013-1611-0. Epub 2013 Apr 12.Cell Tissue Res. 2013.PMID:23579553Free PMC article.Review.
- Adenosine kinase: exploitation for therapeutic gain.Boison D.Boison D.Pharmacol Rev. 2013 Apr 16;65(3):906-43. doi: 10.1124/pr.112.006361. Print 2013 Jul.Pharmacol Rev. 2013.PMID:23592612Free PMC article.Review.
- The APMAP interactome reveals new modulators of APP processing and beta-amyloid production that are altered in Alzheimer's disease.Gerber H, Mosser S, Boury-Jamot B, Stumpe M, Piersigilli A, Goepfert C, Dengjel J, Albrecht U, Magara F, Fraering PC.Gerber H, et al.Acta Neuropathol Commun. 2019 Jan 31;7(1):13. doi: 10.1186/s40478-019-0660-3.Acta Neuropathol Commun. 2019.PMID:30704515Free PMC article.
- In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia.Redrobe JP, Jørgensen M, Christoffersen CT, Montezinho LP, Bastlund JF, Carnerup M, Bundgaard C, Lerdrup L, Plath N.Redrobe JP, et al.Psychopharmacology (Berl). 2014 Aug;231(16):3151-67. doi: 10.1007/s00213-014-3492-7. Epub 2014 Mar 1.Psychopharmacology (Berl). 2014.PMID:24577516
- Mouse pharmacological models of cognitive disruption relevant to schizophrenia.Young JW, Powell SB, Geyer MA.Young JW, et al.Neuropharmacology. 2012 Mar;62(3):1381-90. doi: 10.1016/j.neuropharm.2011.06.013. Epub 2011 Jun 29.Neuropharmacology. 2012.PMID:21726569Free PMC article.Review.
References
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical